At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

This Is Living With Cancer™ is a program designed for those who have been affected by cancer and those who love them. This program is available to anyone in the United States, regardless of age, income, race, location, cancer type or stage of disease. Anyone can use this program, whether they're currently on a Pfizer Oncology treatment or not.

Abbvie's scientific research has led to critical discoveries in the treatment of blood cancer. Now they're expanding knowledge to help treat solid tumors, which represent more than 90% of cancers that affect people.

They leverage deep understanding of human biology and cutting-edge research technologies to find new ways to improve the lives of people with cancer.

Bayer is a global life sciences leader in healthcare and nutrition. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs.

Tolmar’s team of highly-trained research scientists, chemists and engineers work to deliver treatments that advance patient care around the world. With their state-of the-art manufacturing facilities headquartered in Northern Colorado, along with their proven research and development, clinical development, regulatory and production capabilities, Tolmar is an established, sought-after partner.

At Astellas, they are relentless in their pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. They are committed to the realization of greater VALUE by patients and healthcare systems around the world. They achieve this by leveraging their strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

For more than 65 years, Lantheus has been advancing patient care by learning, adapting and making advancements across the healthcare spectrum. We’ve been an instrumental pioneer in the field of medical imaging and, today, we’re reaching further still with novel therapeutics and AI technologies. And we’ll continue to forge ahead with new solutions to new problems—always knowing that someone’s health is in our hands.

We seek partnerships that align with our strategy to solve unmet patient needs through innovation. It’s an entrepreneurial spirit that extends to academic institutions, joint ventures and investment partners. Our openness to creative collaboration makes Lantheus an ideal partner for organizations that share our passion for improved therapeutic, diagnostic and AI technology options for healthcare providers and patients.

Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.

Our vision is to become the most valued and trusted medicines company in the world.

Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.

Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is underpinned by a strong global supply, manufacturing and distribution network.

Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 18 clinical trials underway worldwide.

For more than 25 years, ZERO Prostate Cancer has helped people and families impacted by prostate cancer. ZERO is the primary destination for all impacted by the disease to convene, get support and education, and come together as one united voice to create a better future for the prostate cancer community.